EGFR protein degradant and anti-tumor application thereof
A bifunctional compound, or a pharmaceutically acceptable salt, an isomer, a prodrug, a polymorphic substance or a solvate thereof. The chemical structural formula of the bifunctional compound is represented as formula I, and the bifunctional compound can be used for preventing or treating cancers.
1 . A bifunctional compound of Formula I,
or a pharmaceutically acceptable salt, an isomer, or a solvate thereof, wherein the isomer is selected from: enantiomers, diastereisomers, or cis-trans isomers,
wherein:
(i) the EGFR Binders represents a group shown by the following formula:
ULM represents:
wherein A represents —CH 2 — or —(C═O)—;
B, X, Y, and Z each independently represent CH;
R represents —S—, —CH 2 —, —NH—, —O— or ethynylene;
D is absent; and
LIN represents a linking group covalently bonded to the EGFR Binders and ULM, and represents: —W—(CH 2 ) 2 —, —W—(CH 2 ) 3 —, —W—(CH 2 ) 4 —, —W—(CH 2 ) 5 —, —W—(CH 2 ) 6 —, —W—(CH 2 ) 7 —, —W—(CH 2 ) 8 —, —W—(CH 2 ) 9 —, —W—(CH 2 ) 10 —, —W—(CH 2 ) 11 —, —W—(CH 2 ) 12 —, —W—(CH 2 ) 13 —, —W—(CH 2 ) 14 —, or —W—(CH 2 ) 15 —, wherein W represents —(C═O)—, or W is absent;
or
(ii) the EGFR Binders represents a group shown by the following formula:
ULM represents:
wherein A represents —CH 2 — or —(C═O)—;
B, X, Y, and Z each independently represent CH;
R represents —S—, —CH 2 —, —NH—, —O— or ethynylene;
D is absent; and
LIN represents a linking group covalently bonded to the EGFR Binders and ULM, and represents: —CH 2 -phenylene-CH 2 —;
or
(iii) the EGFR Binders represents a group shown by the following formula:
ULM represents:
wherein A represents —CH 2 — or —(C═O)—;
B, X, Y, and Z each independently represent CH;
R represents —S— or ethynylene;
D is absent; and
LIN represents a linking group covalently bonded to the EGFR Binders and ULM, and represents: —W—(CH 2 ) 2 —, —W—(CH 2 ) 3 —, —W—(CH 2 ) 4 —, —W—(CH 2 ) 5 —, —W—(CH 2 ) 6 —, —W—(CH 2 ) 7 —, —W—(CH 2 ) 8 —, —W—(CH 2 ) 9 —, —W—(CH 2 ) 10 —, —W—(CH 2 ) 11 —, —W—(CH 2 ) 12 —, —W—(CH 2 ) 13 —, —W—(CH 2 ) 14 —, or —W—(CH 2 ) 15 —, wherein W represents —(C═O)—, or W is absent;
or
(iv) the EGFR Binders represents a group shown by the following formula:
ULM represents:
wherein A represents —CH 2 — or —(C═O)—;
B, X, Y, and Z each independently represent CH;
R represents —S—, —NH— or ethynylene;
D is absent; and
LIN represents a linking group covalently bonded to the EGFR Binders and ULM, and represents: —W—(CH 2 ) 2 —, —W—(CH 2 ) 3 —, —W—(CH 2 ) 4 —, —W—(CH 2 ) 5 —, —W—(CH 2 ) 6 —, —W—(CH 2 ) 7 —, —W—(CH 2 ) 8 —, —W—(CH 2 ) 9 —, —W—(CH 2 ) 10 —, —W—(CH 2 ) 11 —, —W—(CH 2 ) 12 —, —W—(CH 2 ) 13 —, —W—(CH 2 ) 14 —, or —W—(CH 2 ) 15 —, wherein W represents —(C═O)—, or W is absent.
2 . The bifunctional compound of claim 1 , or a pharmaceutically acceptable salt, an isomer, or a solvate thereof, wherein the bifunctional compound is a bifunctional compound according to (i), wherein in (i), the ULM represents a group selected from ones shown by the following formulas:
3 . The bifunctional compound of claim 1 , or a pharmaceutically acceptable salt, an isomer, or a solvate thereof, wherein the bifunctional compound is a bifunctional compound according to (ii).
4 . The bifunctional compound of claim 3 , or a pharmaceutically acceptable salt, an isomer, or a solvate thereof, wherein in (ii), the ULM represents a group selected from ones shown by the following formulas:
5 . The bifunctional compound of claim 1 , or a pharmaceutically acceptable salt, an isomer, or a solvate thereof, wherein the bifunctional compound is a bifunctional compound according to (iii).
6 . The bifunctional compound of claim 5 , or a pharmaceutically acceptable salt, an isomer, or a solvate thereof, wherein in (iii), the ULM represents a group selected from ones shown by the following formulas:
7 . The bifunctional compound of claim 1 , or a pharmaceutically acceptable salt, an isomer, or a solvate thereof, wherein the bifunctional compound is a bifunctional compound according to (iv).
8 . The bifunctional compound of claim 7 , or a pharmaceutically acceptable salt, an isomer, or a solvate thereof, wherein in (iv), the ULM represents a group selected from ones shown by the following formulas:
9 . The bifunctional compound of claim 1 , or a pharmaceutically acceptable salt, an isomer, or a solvate thereof, wherein the bifunctional compound is selected from:
10 . The bifunctional compound of claim 1 , or a pharmaceutically acceptable salt, an isomer, or a solvate thereof, wherein the bifunctional compound is a bifunctional compound according to (i).
11 . A pharmaceutical composition comprising the bifunctional compound of claim 1 or a pharmaceutically acceptable salt, an isomer, or a solvate thereof, and at least one pharmaceutically acceptable carrier, an additive, an adjuvant, or an excipient.
12 . A method for regulating epidermal growth factor receptor (EGFR) and/or its mutants, comprising administering to an individual a therapeutically effective amount of the bifunctional compound of claim 1 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the bifunctional compound or pharmaceutically acceptable salt thereof.
13 . A method for treating receptor tyrosine kinase (RTK)-associated diseases, comprising administering to an individual a therapeutically effective amount of the bifunctional compound of claim 1 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the bifunctional compound or pharmaceutically acceptable salt thereof.
14 . A method for treating EGFR-dependent associated diseases, comprising administering to an individual a therapeutically effective amount of the bifunctional compound of claim 1 for a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the bifunctional compound or pharmaceutically acceptable salt thereof.
15 . A method for treating one or more diseases selected from tumors, myeloid tumors, or solid tumors, cancers, leukemia, lymphoma, colorectal cancer, brain cancer, bone cancer, epithelial cell-derived tumors (epithelial cancers), basal cell carcinoma, adenocarcinoma, gastrointestinal cancer, lip cancer, oral cancer, esophageal cancer, small intestine cancer, gastric cancer, colon cancer, liver cancer, bladder cancer, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, squamous cell and/or basal cell carcinoma, prostate cancer, glioma, glioblastoma, renal cell carcinoma and other cancers known to affect systemic epithelial cells, chronic granulocytic leukemia (CML), acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL), comprising administering to an individual a therapeutically effective amount of the bifunctional compound or a pharmaceutically acceptable salt thereof of claim 1 , or a pharmaceutical composition comprising the bifunctional compound or pharmaceutically acceptable salt thereof.
16 . The method of claim 14 , wherein the EGFR-dependent associated diseases are EGFR overexpression- or high EGFR activity-associated diseases.